Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 9/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27171881 | 1.00 | NR1H2 (0.41) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL24695414 | 1.00 | NR1H2 (0.41) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL22620477 | 0.86 | NR1H2 (0.40) | NR1H2RORCUSP2SMN1; SMN2HPGD | |
| SCHEMBL31279010 | 0.86 | NR1H2 (0.42) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL18598985 | 0.86 | NR1H2 (0.42) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL2217516 | 0.84 | RORC (0.40) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL18210065 | 0.84 | RORC (0.40) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL23807876 | 0.83 | EPHX2 (0.42) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL29049020 | 0.83 | EPHX2 (0.42) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL15812124 | 0.83 | EPHX2 (0.42) | NR1H2RORCEPHX2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305014-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-09-29 | — | — | US | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | NR1H2 2168/4885RORC 789/4885EPHX2 3923/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | NR1H2 2168/4885RORC 789/4885EPHX2 3923/4885 |
| US-20220305014-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | NR1H2 2168/4885RORC 789/4885EPHX2 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.